DelveInsights, “Insight into the obesity pipeline, 2022,” the report provides deep insights into over 120 companies and over 120 pipeline drugs in the obesity pipeline landscape. It covers the pipeline drug profiles, including both clinical and non-clinical stage products. It also includes therapeutic evaluation by product type, stage, route of administration and molecule type. It also highlights the inactive pipeline products in this space.
Key takeaways from the Obesity Pipeline Insight Report
- DelveInsights obesity The pipeline report shows a robust space with 120+ active players working to develop 120+ pipeline therapies for obesity.
- The leading obesity companies such as Novartis, Eli Lily & Company, Scohia Pharma, ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Boehringer Ingelheim, Pfizer and others are evaluating the novel obesity Treatment candidates to improve the treatment landscape.
- Promising obesity therapies like VI-0521, THR-4109, PF-06882961, Rosuvastatin, Midazolam, Tirzepatide, Tesofensine and others.
- The companies and scientists are working to assess challenges and seek opportunities that could impact obesity research and development. Therapies under development focus on novel approaches to treat/improve obesity.
- A detailed description of the drug is provided in the report, which includes the drug’s mechanism of action, clinical trials, NDA approvals (if any), and product development activities that include the technology,…
